Scopus Biopharma Inc (NASDAQ:SCPS) stock is trading sharply higher on the FDA news on Monday.
As of 10:26, SCPS stock soared by 136% at $14.10. The stock has traded 3.82 million shares, well above its average volume of 64K shares. The stock opened at $5.74 and moved in a range of $ 5.74- 15.15.
SCPS Releases News
Scopus BioPharma Announces FDA Approval of IND Application for Lead Drug Candidate
- SCPS announced the approval of an investigational new drug application (“IND”) by the United States Food and Drug Administration (“FDA”) for CpG-STAT3siRNA, the company’s distinctive immuno-oncology RNA therapy for the treatment of multiple cancers.
- A Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at City of Hope.
- CpG-STAT3siRNA encompasses both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.
|SHARES OUTSTANDING||15.73 M|
|SHARE FLOAT (%)||5.63 M (35.78%)|
|% HELD BY INSTITUTIONS||3.69|
Recent Stock Performance
|+/- EMA(20)||6.98 (+109.03%)|
|+/- SMA(50)||7.74 (+88.50%)|
|+/- SMA(200)||10.08 (+44.74%)|
|CCI20||-27.6481||Neutral||Chaikin Money Flow||-0.3411||Sell|
|MACD||-0.5851||Sell||Money Flow Index||36.3239||Buy|
|STOCH (14,3)||41.9192||Buy||STOCH RSI||0.9628||OverBought|